{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-073100","form_type":"8-K","ticker":"NKTR","cik":"0000906709","company_name":"NEKTAR THERAPEUTICS","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.655352+00:00","generated_at":"2026-05-17T18:45:11.114549+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nektar Q2 net loss $41.6M; rezpegaldesleukin Fast Track; cash runway into Q1 2027","bullets":["Revenue $11.2M Q2 2025 vs $23.5M Q2 2024; decrease due to sale of Huntsville facility.","Net loss $41.6M ($2.95 per share) vs $52.4M loss ($3.76 per share) in Q2 2024.","Cash and investments $175.9M at June 30, 2025; excludes $107.5M net proceeds from July 2025 offering; runway into Q1 2027.","FDA Fast Track granted for rezpegaldesleukin in severe-to-very severe alopecia areata (July 2025).","REZOLVE-AD Phase 2b met primary and key secondary endpoints at week 16; 52-week data expected early 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-073100","json":"https://secwatch.observer/filing/0001213900-25-073100.json","markdown":"https://secwatch.observer/filing/0001213900-25-073100.md","text":"https://secwatch.observer/filing/0001213900-25-073100.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000121390025073100/0001213900-25-073100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000121390025073100/ea0252183-8k_nektar.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:45:11.114549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}